

Date: 08th February 2026

To,
 Manager - Listing Compliance
National Stock Exchange of India Limited
 'Exchange Plaza'. C-1, Block G,
 Bandra Kurla Complex, Bandra (E),
 Mumbai - 400 051
 SYMBOL: JSLL

To,
 Head of the Department,
 Department of Listing Operation,
BSE Limited
 Phiroze Jeejeebhoy Towers,
 Dalal Street, Mumbai 400001
 SCRIP Code: 544476

**Sub: Investor Presentation under Regulation 30 read with Para A of Part A of Schedule III of the
 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Ma'am,

In continuation of our earlier communication dated February 04, 2026, regarding the schedule of the conference call (Group Conference call) to discuss the financial performance of the Company for the Q3 (FY 2025-26), please find enclosed the Investor Presentation of the Company for the Q3 (FY 2025-26) pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This presentation is being used during meeting with investors scheduled on Monday, February 09, 2026.

The Investor Presentation is also being disseminated on Company's website at www.jeenasikho.com

Kindly take the above information on record.

**Thanking you,
 Yours faithfully,**

For Jeena Sikho Lifecare Limited

**Manish Grover
 Managing Director
 DIN: 07557886**

Place: Zirakpur, Punjab

JEENA SIKHO LIFECARE LIMITED

120⁺ AYURVEDA CLINICS & HOSPITALS | FREEDOM FROM 2D DISEASES & DRUGS

Registered Office Address:
 SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
 Punjab-140604, 01762-513185
 CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
 B-26, Opp. Metro Pillar No. 223, Rohtak Road,
 New Multan Nagar, Delhi - 110056
 Email ID: cs@jeenasikho.com | www.jeenasikho.com



वसुधैव कुटुम्बकम्
ONE EARTH • ONE FAMILY • ONE FUTURE



One World, One Health

Heal In India



Dr. Sonali

Homeopathic Physician
Expert in Relationship, Intimacy
& Sexual Health Concerns

Prof. Ish Sharma

MD, Ph.D Ayurveda
Former Ayurveda Ambassador
In Mauritius

Acharya Manish Ji

Naturopathy & Diet Expert
Guiding Globe Towards Drug-Free,
Natural Wellness

Dr. BRC

Ph.D, Diabetes
Chairman, Indian Book
Of Records

Dr. Neha Sharma

BAMS, ACLS – Autism Specialist
Head, Virtual OPD Department



Empowering Holistic Health & Wellness

Jeena Sikho Lifecare Limited



120+ Ayurveda Clinics & Hospitals | Freedom from 2D: Diseases & Drugs

Investor Presentation

Q3 FY26 | February 2026





Table of *Contents*

01

Quarterly Performance
Highlights

**Key Financial Milestones
and Insights**

03

Unique Business Model
Positioning

**Differentiated Market Approach
and Competitive Advantage**

05

Way Forward

**Vision, Strategy, and
Roadmap**

02

Introduction
to JSLL

**Company Overview and
Strategic Foundation**

04

Breadth of
Operations

Reach of Our Operations

06

Annual Financial Highlights

**Key Financial Milestones
and Insights**




01

Quarterly
*Performance
Highlights*

Q3FY26 *Performance Highlights*

Revenue from Operations (In ₹ Crore)

▲ 17%
QoQ change ▲ 92%
YoY change




EBITDA & EBITDA Margin (In ₹ Crore & %)

26%
Q3FY25

48%

45%
Q3FY26



PAT & PAT Margin (In ₹ Crore & %)

▲ 14%
QoQ change ▲ 405%
YoY change




Revenue-Mix (In ₹ Crore)



Note: Post migration to mainboard the Company has shifted to Ind AS Accounting Standards

Q3FY26 *Income Statement*




PARTICULARS	Q3FY25	Q2FY26	Q3FY26	YoY CHANGE (%)	QoQ CHANGE (%)
REVENUE FROM OPERATIONS	11,569	18,985	22,166	92%	17%
GROSS PROFIT	9,991	16,576	19,751	98%	19%
GROSS PROFIT MARGIN (%)	86%	87%	89%	274 BPS	179 BPS
OPERATING EXPENSES	7,030	7,370	9,671	38%	31%
EBITDA	2,961	9,206	10,080	240%	9%
EBITDA MARGIN (%)	26%	48%	45%	1,988 BPS	-302 BPS
DEPRECIATION & AMORTISATION	847	1,040	1,121	32%	8%
EBIT	2,114	8,166	8,959	324%	10%
FINANCE COST	379	435	310	-18%	-29%
OTHER INCOME	39	144	257	558%	78%
PROFIT BEFORE TAXES	1,774	7,876	8,906	402%	13%
TAXES	453	1,998	2,233	393%	12%
PROFIT AFTER TAXES	1,321	5,878	6,673	405%	14%
PROFIT AFTER TAXES MARGIN (%)	11%	31%	30%	1,838 BPS	-97 BPS
BASIC EARNINGS PER SHARE (₹)	1.06	4.73	5.37	407%	14%

Note: Post migration to mainboard the Company has shifted to Ind AS Accounting Standards

Q3FY26 *Operating Metrics*


IPD Patient Volumes (#)

▲ 18% ▲ 84%
QoQ change YoY change




OPD Patient Volumes (# Lakhs)

▲ 12% ▲ 89%
QoQ change YoY change




Day Care Volumes (#)

▲ 11% ▲ 139%
QoQ change YoY change




OPD, COD & VC Patients (# Lakhs)

▲ 68% ▲ 247%
QoQ change YoY change



Video-Call Consultations (#)

▲ 8% ▲ 214%
QoQ change YoY change



Management *Commentary*



Jeena Sikho has delivered yet another robust quarter, continuing its strong momentum from the first half of FY26. The Company's performance in Q3 further strengthens its track record of consistent growth and operational excellence, with solid contributions from both business verticals, Ayurveda Healthcare Services and Ayurveda Healthcare Products.

Revenue from Operations grew by an impressive 92% YOY in Q3 and 78% YOY for 9MFY26. This growth was primarily driven by sustained volume expansion across business segments and the continued strengthening of our pan-India presence.

Profitability remained on a strong footing, with EBITDA margins steady at 45% in Q3, reflecting operational efficiency despite ongoing investments in business expansion. On a year-to-date basis, 9MFY26 EBITDA margins improved significantly to 46%, compared to 29% in FY25, underscoring the growing scalability and efficiency of our business model.

In our services segment, patient volumes remained robust across both IPD and OPD formats, resulting in higher throughput and overall service revenue. Our Day Care centres and Video-Call consultations have shown tremendous traction, further augmenting our reach and accessibility. The Company continues to benefit from increasing nationwide awareness and acceptance of Ayurvedic healthcare solutions.

Looking ahead, the services business is well-positioned to deliver sustained growth, supported by a strong bed pipeline. We currently have 475+ beds under development, providing good visibility for capacity additions across existing and new facilities, which will drive further volume-led growth in the coming quarters.

On the innovation front, we are gearing up to launch the Jeena Sikho Health Card, an initiative designed to offer enhanced value and convenience to our customers. More details on this will be shared in the upcoming quarters.


Our Ayurveda healthcare products segment also continues to gain momentum, supported by successful recent product launches and growing demand for our legacy portfolio. The category's strong performance validates our strategy of product diversification and consistent focus on quality and innovation.

In conclusion, Jeena Sikho remains firmly positioned to sustain its strong growth trajectory. With strategic initiatives in capacity expansion, market diversification (including international expansion), operational excellence, and a differentiated product portfolio, the Company is well-prepared to deliver consistent growth and long-term value for all stakeholders.


Acharya Manish Ji

MANAGING DIRECTOR





02



Introduction to
*Jeena Sikho
Lifecare*

An emerging health crises:

Modern healthcare, while advancing rapidly, often brings unintended side effects that can compromise overall well-being. Despite significant investments of time, resources, and trust, many individuals continue to experience persistent health issues and increasing dependency on medications. Environmental factors such as contaminated water, adulterated food, and reduced connection with nature further contributes to a gradual decline in health.

Quick symptomatic treatments frequently address only the surface of these problems, providing temporary relief rather than lasting solutions. This cycle of dependency underscores the need for a more holistic approach.



A leap towards true healing:

After years of research and demonstrable outcomes, Acharya Manish Ji advocates for Ayurveda as a principal healthcare approach. Rooted in ancient wisdom and supported by real-world results, Ayurveda emphasizes balance of body, mind, and spirit, aiming to address the root cause of illness rather than merely suppressing symptoms.

Through gentle, non-invasive therapies, Ayurveda offers a path to sustainable health, even for chronic health conditions. Embracing these principles enable individuals to reduce dependency on pharmaceuticals and move towards a healthier, more balanced life.

Introduction to *Jeena Sikho Lifecare*

India's Leading ayurveda healthcare service provider



58

Operational hospitals



2,800

Total Beds

2,290

Beds operational



510 Beds

Recently Added



100+

Cities & towns covered



59

Operational clinics & day CARE CENTRES

475

Beds in pipeline

23

States covered

330+

SKUs in Ayurveda medicine & product portfolio



47%

3Y Top line CAGR[^] - One of the fastest growing healthcare enterprise



NSE

Listed on NSE since April 2022



71%

ROCE* - Capital-light business model



Migrated

Migrated to NSE & BSE mainboard in August 2025

Journey so far




An idea is born

2009

The idea of **Jeena Sikho** was born

Active Hospitals and Clinics & Day Cares (#)



Clinics & Day Cares Hospitals

Jeena Sikho Lifecare Limited

Initial products & medicines business commences

2009

Commenced ayurveda medicine & product sales



Holistic health care services added to the fold

2013

Established **first ayurveda health care centre** in Chandigarh

2017

Jeena Sikho Lifecare was incorporated as a company

2018

Developed the **Shuddhi Project** to setup dedicated ayurveda health care centres

2020

Inaugurated **Derabassi centre – Jeena Sikho Panchakarma Hospital**

2021

Surpassed **50 operational centres** across the country

Raised growth capital to expand in both verticals

2022

Successfully raised **₹55.5 Cr** from IPO

2023

Opened centres in **Lucknow, Jaipur, Navi Mumbai** among **20 other small-mid centre** across the country

2024

Achieved landmark revenue of **₹324 Cr**

2025

Surpassed **1,600 operational bed capacity** with newly added 573 beds, across total 77 units



About the *founder*

Acharya Manish Ji:

Advancing Ancient Ayurvedic Science Through Modern, Nobel-Worthy Research


Fueled by a powerful vision of a Disease-Free, Drug-Free Bharat, Acharya Manish Ji's unwavering faith in Ayurveda took root and flourished.

Through years of in-depth research in Ayurveda and Naturopathy, he uncovered what ancient sages always knew - true healing lies in nature, not in chemicals. Recognizing that **Ayurveda is India's gift to the world - a science born in India to heal India and beyond - "We Heal in India,"** he pioneered a system where health is restored through nature rather than dependence on pharmaceuticals.

Understanding Ayurveda's ability to treat chronic and critical illness without harmful side effects, he initiated the revolutionary **Golden Therapy — a transformative treatment now offering hope to countless lives.** Today, people have the opportunity to pursue good health, a peaceful mind, and a nurtured soul - all at once.

More than just treatment, Acharya Ji advocates a **national awakening:** a Bharat where every individual becomes their own healer. His mantra, "अपना डॉक्टर खुद बनो," isn't just a slogan — it is a movement to reclaim our health, roots, and inner wisdom.

Our scientific foundation supports this vision - our research includes the Nobel Prize-recognized Seed & Soil Theory (1895), along with multiple other validated scientific frameworks explored across 1927, 1931, 1998, 2016, 2017 and 2019.



Extensive Experience and Mastery


Driven by a passion for natural healing, Acharya Manish Ji has dedicated his life in making ancient Ayurvedic wisdom accessible and practical for modern living. Through Jeena Sikho Lifecare, he has built a nationwide network of wellness centers and clinics, offering personalized care that address the root cause of disease. His educational initiative—ranging from television programmes to social media content and community health camps—have empowered lakhs of people to take charge of their health using Ayurveda's principles of detoxification, rejuvenation, and balance.

Societal Impact

Acharya Manish Ji envisions a world where holistic health is not a privilege but a universal right. He is committed in breaking down barriers to Ayurvedic care, expanding its reach both across India and globally. His mission centers on transforming healthcare by combining ancient wisdom with innovative approach, ensuring that every individual can experience the benefit of natural healing.

Through relentless advocacy, quality-driven practice, and a focus on education, Acharya Manish Ji continues to inspire a healthier, more balanced society.

Seed and Soil Theory (1889)



Stephen Paget



THE
NOBEL
PRIZE

- **Proposed by:** Stephen Paget (English surgeon and pathologist) Year: 1889
- *"The distribution of secondary growths in cancer of the breast."*
- **Published in:** The Lancet, 1889.

What is it?


Stephen Paget introduced the **"Seed and Soil Hypothesis"** to explain **why metastatic tumors form in specific organs** and not randomly in the body.

- **Seed** = Cancer cells (metastatic cells)
- **Soil** = Target organ microenvironment

Main idea

Just like a seed can only grow in fertile soil, *cancer cells ("seeds") can only successfully grow and form secondary tumors if they land in a suitable environment ("soil")* —that is, tissues/organs with favorable conditions for their growth.

Julius Wagner-Jauregg (1927)



Julius Wagner-Jauregg



THE
NOBEL
PRIZE

Fever is our Friend

- Nobel Prize in Physiology or Medicine 1927
- **Affiliation at the time of the award:** Vienna University, Vienna, Austria
- **Prize motivation:** "for his discovery of the therapeutic value of malaria inoculation in the treatment of dementia paralytica"

Work

The Nobel Prize in Physiology or Medicine 1927 was awarded to Julius Wagner-Jauregg "for his discovery of the therapeutic value of malaria inoculation in the treatment of dementia paralytica"

Otto Heinrich Warburg (1931)



Otto Heinrich Warburg



THE
NOBEL
PRIZE



Facts

- Nobel Prize in Physiology or Medicine 1931
- **Affiliation at the time of the award:** Kaiser-Wilhelm-Institut (now Max-Planck-Institut) für Biologie, Berlin-Dahlem, Germany
- **Prize motivation:** "for his discovery of the nature and mode of action of the respiratory enzyme"

Work

He Suggested that the prime cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar.

Nobel Prize *in Physiology or Medicine (1998)*



Robert F. Furchtgott

Louis J. Ignarro


Ferid Murad

THE
NOBEL
PRIZE

Work

The Nobel Prize in Physiology or Medicine 1998 was awarded jointly to Robert F. Furchtgott, Louis J. Ignarro and Ferid Murad *"for their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system"*. Their work established that nitric oxide acts as a messenger in the body, allowing blood vessels to relax and dilate, which has implications for treating conditions like erectile dysfunction and heart disease.

Yoshinori Ohsumi (2016)



THE
NOBEL
PRIZE

Facts

- Nobel Prize in Physiology or Medicine 2016
- **Affiliation at the time of the award:** Tokyo Institute of Technology, Tokyo, Japan
- **Prize motivation:** "for his discoveries of mechanisms for autophagy"


Work

The 2016 Nobel Prize in Physiology or Medicine was awarded to Japanese cell biologist Yoshinori Ohsumi *for his discoveries concerning the mechanisms of autophagy*. His work identified the key genes and processes involved in how cells degrade and recycle their own components, a crucial function for cell health.

Yoshinori Ohsumi



Nobel Prize *in Physiology or Medicine (2017)*



Jeffrey C. Hall



Michael Rosbash



Michael W. Young

THE
NOBEL
PRIZE

Work

The 2017 Nobel Prize in Physiology or Medicine was awarded to Jeffrey C. Hall, Michael Rosbash, and Michael W. Young *for their discoveries of the molecular mechanisms controlling circadian rhythms.* Their work identified the genes and proteins that regulate the internal biological clock, which aligns an organism's internal rhythm with the Earth's rotation. This research explained how the body regulates sleep, behavior, and hormone levels, and how disruptions to this clock can negatively impact health.

Guiding Force behind Jeena Sikho



Mr. Manish Grover
Managing Director

Ms. Bhavna Grover
Whole Time Director

Advocate Ms. Shreya Grover
Whole Time Director

Mr. Karanvir Singh Bindra
Independent Director

Mr. Chandan Kumar Kaushal
Independent Director
Retired From AYUSH Dept. Punjab

Ms. Priyanka Bansal
Independent Director



Mr. Sahil Jain
Chief Operating Officer

Mr. Nanak Chand
Chief Financial Officer

Ms. Smita Chaturvedi
Company Secretary

Mr. Gaurav Mohan Garg
Business Development Head

Dr. Ish Sharma
Director
Medical Services & Research

Dr. Avira Gautam
BAMS, MD (Ayurveda),
PhD, MBA
Renowned for Ayurvedic care in chronic and lifestyle disorders

Ms. Akansha Jain
HR Head

Mr. Mukesh Grover
Administration Head

Mr. Ishan Goel
Chief Marketing Head – Social Media

Dr. Neha Sharma
BAMS/ACLS, Autism Head Virtual VOPD Department

Ms. Namrta Chaudhary
Client Support Centre Head

Dr. Sonali
Homeopathic Physician
Expert in Relationship, Intimacy & Sexual Health Concerns

A woman with dark hair is smiling while receiving a head massage. A large, shiny golden bowl is positioned above her head, with some liquid or oil dripping down. The background is a soft, out-of-focus light color.

03

Unique Business
*Model
Positioning*

Superior *Business Model Positioning*

A unique combination of product & service revenue stream



Ayurveda health care services

- Operated out of hospitals & clinics through a hub & spoke model
- CAPEX & OPEX-light operational structure
- Significant operating leverage beyond break-even occupancy levels of assets

₹288 Cr

Revenue (9MFY26)

49%

Contribution (9MFY26)



Ayurveda health care products

- Sales generation out of company health care centres, tele-calling centre, and e-com
- Product portfolio with ~85% gross margins
- Manufacturing outsourced to a reliable network of third-party manufacturers
- Healthy cash generation from this vertical

₹298 Cr

Revenue (9MFY26)

51%

Contribution (9MFY26)




Significant synergies between the two verticals

Significant cross-selling & lead-generation opportunities between both verticals:

1. Medicine/product customers visit health care centres for a more holistic treatment
2. Health care centres patient's consume medicines for medium-to-long tenure post-treatment

JSLL's *Business Structure*



Unique business model

1. To benefit from significant operating leverage of services vertical
2. Well-supported by healthy cash-generation from high-margin products vertical
3. Significant cross-selling & synergies between both the verticals

JSLL's *Unique Capital-light Approach*



Low CAPEX per bed

- Setup cost of ₹3-4 lakh per bed (a typical 100 bed facility)
- Setup at custom-made leased facilities
- Limited investments in panchakarma bed & equipments



Mix of own & franchise assets

- 35/117 facilities are under franchisees: typically, clinics & day care are operated by franchisees
- Investment & day-to-day operations run by franchisees
- Ayurveda doctors at franchisees on JSLL's payroll & ayurveda medicines exclusively supplied by JSLL



Unique hub-and-spoke model

- Clinics & day-care facilities feeding sales funnel of hospitals in the vicinity
- OPD footfall driving IPD volumes




Capital-light business model

Resulting in:

1. Superior ROCE's – 71%*
2. Ability to scale rapidly
3. Nurturing a robust balance sheet (debt-free)

*3Y Average ROCE

JSLL's *Flywheel Effect*



Robust *Sales Funnel*



Social Media Channels:

youtube.com/@acharyamanishji
1.24M subscribers | **4.8K** videos
facebook.com/GuruManishAyurveda
2.4M Followers
instagram.com/acharyamanishji
1.5M followers
youtube.com/@HIIMSOFFICIAL
690K subscribers | **4.2K** videos
facebook.com/hiimsofficial
2M followers
instagram.com/hiimsofficial
989K followers
youtube.com/@haveshuddhi
578K subscribers | **3.5K** videos
facebook.com/HaveShuddhi
931K Followers
instagram.com/haveshuddhi
331K followers
youtube.com/@jeenasikhoshop
2.68K subscribers | **284** videos
facebook.com/jeenasikhoshop/
2.4M Followers
instagram.com/jeenasikhoshop
52.7K followers

facebook.com/PetShuddhi/
599K followers
instagram.com/petshuddhi/
266K followers
youtube.com/@Khul_Ke_Pucho
217K subscribers | **120** videos
facebook.com/khulkepucho
29K Followers
instagram.com/khul.kepucho
13.9K followers

Client Support Centre:

Continuously & proactively in touch with customers through Client Support Centre marketing

National & Regional Presence:



Proactive Social Media Presence

Client Support Centre Marketing

Presence on National & Regional TV, Radio, News Papers and Cinema

E-Com Sales Channel



4

72-hour health care camps organised (Q3FY26)

340


Cumulative visitors at health care camps (Q3FY26)

Health care camps serving as a direct source of revenue as well as leads for hospitals

Cumulative OPD, COD & VC customers served:
(In Lakhs)



All resulting in growing IPD volumes:
(#)



Attractive *Unit Economics*



Typical CAPEX of a 100-bed facility

Furniture & fixtures:
~₹45-50 lakhs
Medical equipment:
~₹60-65 lakhs
Others-Infra (varying at each facility):
~₹150-250 lakhs

Total: ₹250-350 lakhs

Per bed: ₹3-4 lakhs



OPEX of a 100-bed facility (monthly)

Fixed Costs
Typical team size:

- ~20 ayurveda doctors
- ~80 support-staff
- ~100 contractual staff

₹50-55 lakhs monthly payroll

Rent
₹10-12 lakhs monthly depending upon location

Variable Costs
Minimal consumables, electricity & operating expenditure
~12-15% of sales



Revenue potential

₹8,337/day/bed*
Bundled of Panchakarma service per day per bed

~₹300 lakhs#
monthly revenue potential at 100% occupancy levels of a 100-bed facility

~35%
Approximate break-even occupancy levels as per standard operating expense structure

*Rounded off

#Including sale of medicines



Swift paybacks Superior ROCEs (%)

12-18 months
for a hospital to reach 70% (respectable utilization)

Payback period of investment
<6 months, even lesser for smaller hospitals

Positioned for *Leadership*



Insurance & Government Panel


Insurance Empanelment's



Government Panel

- Empanelled for treatment of government employees of **Uttar Pradesh, Bihar, Haryana and Punjab**, with direct settlement of eligible medical bills as per state norms.
- Empanelled with **CGHS, CAPF and ECHS** for comprehensive healthcare services to beneficiaries.
- Also empanelled with: **DDA, CBSE, CSIR, DERC, DHC, BIS, Narmada Control Authority, Haryana Govt Employee Panel, TRAI, CERC, NHAI, MMTC, IWAI, DFCCIL, Air India, GAIL (India) Limited, GYPSA, MPPGCL, Navodaya, Maruti Suzuki Limited** and leading private insurance companies.

Fintech-Financing



CAPF

The seven central armed police forces



AR – Assam Rifles

BSF – Border Security Force

CISF – Central Industrial Security Force

CRPF – Central Reserve Police Force

ITBP – Indo-Tibetan Border Police

NSG – National Security Guard

SSB – Sashastra Seema Bal



Franchisees

35

franchisee operated health care centres

CAPEX & OPEX

(ex-doctor payroll) borne by franchisee partner

Ensuring quality through exclusive JSLL team & products

- Ayurveda doctors & medical staff at franchise centres on JSLL's payroll
- Exclusive sales of JSLL's ayurveda product portfolio through bundled offerings (consultation + products)



Doctors & Medical Staff

~575

Certified ayurveda doctors

~750

Supporting health care personnel



Incentive structures of doctors aligned to serve patients well & run efficient operations



Patients

Enabling quality & affordable alternate health care solutions

Superior customer support service through dedicated health care contact centre

Patient-centric approach generating repeat business

Word-of-mouth is the best marketing tool

Positioned for *Leadership*

Market leadership

- Leading organised player in Ayurveda healthcare chain with 49 NABH accredited hospitals & clinics
- Further, additional 3 NABH accreditations for AYUSH Hospitals in pipeline



49 + 3

Actual | In-Pipeline
NABH Accredited
Hospitals & Clinics

NABH Accredited data as
on 31st December 2025



Humongous size of opportunity

- India has an estimated ~1.9 million hospital beds as per CDDEP
- There is a large, unserved need for alternate medicine



Corporate governance

1. Consistent & growing dividend payout in FY23, FY24 and FY25
2. Audit committee chaired by an Independent Director
3. Engaging in regular investor communication through presentations & conference calls
4. Migrated to mainboard after meeting all mainboard listing criteria's in August 2025





04

Breadth of
Operations

Hub-and-spoke *Geographical Expansion*

58

Hospital

59

Clinics & daycare centres

23

States

100+

Cities & Towns

2,290

Beds operational

510 Beds

Recently added

475


Beds in pipeline

6

Facilities in pipeline



Assam	1 hospital
Bihar	1 hospital 10 franchise
Chandigarh	1 hospital
Chhattisgarh	2 hospital 1 franchise
Delhi	3 hospital 7 clinic 1 franchise
Goa	1 hospital
Gujarat	3 hospital 1 clinic 1 franchise
Haryana	6 hospital 1 clinic 5 franchise
Himachal Pradesh	2 clinics
Jammu and Kashmir	1 hospital
Jharkhand	2 hospital 1 franchise
Karnataka	1 hospital
Maharashtra	5 hospital 1 clinic 4 franchise
Madhya Pradesh	2 hospital 1 clinic 1 franchise
Odisha	2 franchise
Punjab	3 hospital 6 clinic 1 franchise
Rajasthan	10 hospital
Tamil Nadu	1 hospital
Telangana	1 hospital
Tripura	1 franchise
Uttar Pradesh	12 hospital 3 clinic 5 franchise
Uttarakhand	1 hospital 1 franchise
West Bengal	1 hospital 2 clinic 1 franchise





Key *Health Care Facilities*

Meerut,
Uttar Pradesh

Since
Dec-2022

612
Beds

NABH
Accredited



Lucknow,
Uttar Pradesh

Since
Jun-2022

115
Beds

NABH
Accredited



Derabassi,
Punjab nearby
Chandigarh

Since
Oct-2020

113
Beds

NABH
Accredited



Navi Mumbai,
Maharashtra

Since
Nov-2022

163
Beds

NABH
Accredited



Key *Health Care Facilities*



*Panchkula,
Haryana*

Since
Aug-2024

70
Beds

NABH
Accredited



*Manesar,
Gurugram*

Since
May-2025

100
Beds



*Panvel,
Mumbai*

Since
Oct-2025

230
Beds



Health Care Camps *Case Studies*



We conduct regular health care camps each month

Average ~30% conversion of camp attendees for IPD treatments



Jeena Sikho Lifecare Limited

Meerut Camp

Dates: 25th to 28th December

State name: Uttar Pradesh

Duration: 4 days

61

Visitors Attended

~₹31 lakhs

Direct Business Garnered

Meerut Camp

Dates: 5th to 7th December

State name: Uttar Pradesh

Duration: 3 days

115

Visitors Attended

~₹61 lakhs

Direct Business Garnered

Meerut Camp

Dates: 20th to 23rd November

State name: Uttar Pradesh

Duration: 4 days

58

Visitors Attended

~₹30 lakhs

Direct Business Garnered

Meerut Camp

Dates: 30th October to 2nd November

State name: Uttar Pradesh

Duration: 4 days

106

Visitors Attended

~₹55 lakhs

Direct Business Garnered

Meerut Camp

Dates: 26th to 28th September

State name: Uttar Pradesh

Duration: 3 days

136

Visitors Attended

~₹58 lakhs

Direct Business Garnered

Meerut Camp

Dates: 29th to 31st August

State name: Uttar Pradesh

Duration: 3 days

129

Visitors Attended

~₹62 lakhs

Direct Business Garnered

Health Research Published by *Jeena Sikho*



*Clinical Trial
Report*



*Research Papers
Published*



Comprehensive *Healthcare Services* – 1/2

Health Care Services Offered



In-patient
Department
(IpD) Through
Hospitals



Out-patient
Department
(OpD) Via Clinics
& Daycare Centres



72-hour
Health
Camps



Panchakarma
Therapies



Medical-kits



Diet Care



Comprehensive *Healthcare Services* – 2/2

Ailments Treated



Thyroid



Obesity & Weight Loss



Cholesterol



Migraine



Depression



Joint Pain



Back Pain



Eye Treatment



Acidity & Gas



Anxiety



Psoriasis



Ulcer



Sexually Transmitted Diseases



Fissure



Skincare



Leukoderma



Asthma

Ayurveda *Product Portfolio*

Our Top Selling Products



Existing sales channels

1. Client support centres & e-com
2. At health care centres

Tapping OTC sales channel at pharmacies with new product launches

330+
SKUs in portfolio

~85%
Overall Gross Margin in product



OTC Product Portfolio

Product Launched

Pet Yakrit Pleeha Shuddhi Kit



Dr. BP Care DS



Dr. Kidney Care DS



Dr. Madhu Care DS



Dr. Liver DS




Dr. Sukoon DS



All products compliant with AYUSH Standards

Upcoming Products in Categories

1. Plant Based Protein Powder
2. Gyno Syrup
3. Joint Pain Oil
4. Joint Pain Ointment
5. Joint Pain Balm
6. Joint Pain Tablets



Client Support Centre Operations

Dedicated health care Client Support Centre for proactive sales & customer support operations:

Driving customer order placement & processing for medicine portfolio

Ensuring repeat business & continued association with customers

Consumer support & grievance redressal

Facilitating sales leads for health care centres


Administering virtual & telephonic consultation through in-house doctors

Guidance on insurance facilities



Video-call Consultations

(#)



Upcoming Schemes



Customer *Testimonials*

Ashwini Upadhyay *Advocate Of Supreme Court* *(PIL Man of India)*

When top hospitals recommended knee surgery for his father, he came to our HIMS Chandigarh centre - just ten days of Ayurvedic and rehab care had his father walking pain-free, no surgery needed. These recoveries show our commitment to effective, affordable healing.

[VIEW THE VIDEO](#)


Suresh Chavhanke *(Owner Sudarshan News)*

A respected journalist brought his father - told he needed surgery - to Jeena Sikho. Just two and a half weeks of Ayurvedic and Panchakarma care, his father's reports came back clear. A powerful example of our compassionate, evidence-based healing.

[VIEW THE VIDEO](#)


Avadh Ojha *(Renowned UPSC Teacher)*

Due to an irregular lifestyle, Avadh Ojha developed diabetes. By following the DIP Diet recommended by Acharya Manish Ji, he achieved complete recovery without any medication. Mr. Ojha believes Acharya Ji is a true servant of humanity, whose guidance not only heals illnesses but also helps overcome stress and depression.

[VIEW THE VIDEO](#)


Comedian Bharti Singh's Mother

When Mrs. Singh was admitted to our facility, allopathic doctors had advised her to take dialyses but she avoided this course of action. Since she began her treatment, she noticed significant improvement in her health. She was on insulin for 12-15 years before she came to Jeena Sikho Lifecare. Within 4 days, she was off the insulin and get rid of BP tablet.

[VIEW THE VIDEO](#)


Ganesh Ji *(Defeated Blood Cancer)*

Ganesh Ji was diagnosed with 52 lumps in his body and severe swelling, leaving him dependent on a wheelchair. After one month of Ayurvedic and natural therapy at Jeena Sikho HiiMS, his swelling reduced, lumps subsided, and he regained mobility and improved health.

[VIEW THE VIDEO](#)


Prahlad Modi *(Brother Of PM Narendra Modi)*

When Modi ji's brother came to us he used to undergo dialyses thrice a week wherein 4.5 litres of water was removed from his body. Now the water content has reduced to 3 litres and he is looking forward to being free from dialysis soon.

[VIEW THE VIDEO](#)


Rajiv Thakur *(Renowned Comedian)*

When our clients' parents came to Jeena Sikho after years of declining health, Acharya Manish's personalized Ayurvedic care began reversing chronic issues within just three months. Half of their conditions have already healed, with steady progress on the rest. More than caregivers, our team fearlessly advocates for patients, challenging medical doubt with results.

[VIEW THE VIDEO](#)


PM Narendra Modi *on the Power of Ayurveda*

Prime Minister Narendra Modi shared how his close friend, **Kenyan leader Raila Odinga's daughter, Ms. Rosemary Odinga**, regained her eyesight after receiving **Ayurvedic treatment in India**. He highlighted this as a powerful example of how India's ancient Ayurvedic wisdom continues to offer hope and healing to the world.

[VIEW THE VIDEO](#)


Bollywood Actor *Akshay Kumar* *on Ayurveda & Body* *"Servicing"*

Akshay Kumar shares that he has been following **Ayurveda for over 25 years** and even stays at Ayurvedic centres to experience deep healing. He explains that just as we regularly service a car, we must also "service" our body through **Ayurveda, Yoga, Naturopathy, Siddha, Unani and Homeopathy** to maintain health and prevent disease.

[VIEW THE VIDEO](#)


Gulab Chand Kataria *Governor Punjab*

Governor Gulab Chand Kataria warmly praised Acharya Manish Ji and the role of Ayurveda in promoting holistic health and Indian traditional wisdom. He appreciated the efforts being made to take authentic Ayurvedic care to the masses and inspire people towards a healthier lifestyle.

[VIEW THE VIDEO](#)


Justice Kolsé Patil *(Retd. Judge of Mumbai High Court)*

Justice Kolsé Patil Ji's blood sugar reached 500. By leaving all allopathic medicines and following only the DIP Diet and exercise, his sugar levels normalized within a short time. His wife's glaucoma also improved, with doctors declaring no further treatment needed. This experience shows that diabetes can be controlled through the DIP Diet and Ayurvedic lifestyle.

[VIEW THE VIDEO](#)


Arun Sharma *National President Media Federation Of India*

Arun Sharma, National President, Media Federation of India, shared that he had lost the vision in one eye. After taking treatment at our Delhi hospital, the eyesight in that eye returned within just 10 days. He describes this recovery as nothing short of a miracle for him.


[VIEW THE VIDEO](#)




05

Way

Forward



Outlook

- 01 Improve utilization rates of existing assets
- 02 Launch new centres & bed addition in existing centres
- 03 Tap OTC sales channel for medicine sales
- 04 Expand portfolio: launch new products
- 05 Enablement of cashless insurance to aid volumes
- 06 Expected increase in coverage under Government Panel / AYUSH
- 07 Overseas Expansion beginning with U.A.E.






06

Annual
*Financial
Highlights*

Key *Operating Metrics*

Operational Beds & Occupancy (#)



Avg. Revenue Per Bed* (In ₹)



IPD Patient Volumes (#)




OPD Patient Volumes (# Lakh)




Medicine Order Volumes (# Lakh)




Revenue-mix (In ₹ Crore)




Govt. Panel Revenue (In ₹ Crore & %)



Active Operational Centres (#)




5Y *Income Statement*



PARTICULARS	FY21	FY22	FY23	FY24	FY25
REVENUE FROM OPERATIONS	13,581	14,645	20,390	32,441	46,907
GROSS PROFIT	11,884	12,971	18,193	29,298	41,084
GROSS PROFIT MARGIN (%)	88%	89%	89%	90%	88%
OPERATING EXPENSES	10,196	11,159	13,586	19,999	28,596
EBITDA	1,688	1,812	4,608	9,299	12,488
EBITDA MARGIN (%)	12%	12%	23%	29%	27%
DEPRECIATION & AMORTISATION	246	331	313	510	871
EBIT	1,442	1,482	4,295	8,789	11,617
FINANCE COST	130	114	70	41	51
OTHER INCOME	107	149	228	644	641
PROFIT BEFORE TAXES	1,419	1,517	4,453	9,392	12,207
TAXES	389	390	1,079	2,471	3,134
PROFIT AFTER TAXES	1,029	1,127	3,374	6,921	9,073
PROFIT AFTER TAXES MARGIN (%)	8%	8%	16%	21%	19%
EARNINGS PER SHARE (₹)	10.19	11.15	13.69	27.84	36.50


Note: EPS for FY24 & FY23 takes into account bonus shares issued in November 2023

5Y *Balance Sheet*



PARTICULARS	FY21	FY22	FY23	FY24	FY25
TOTAL EQUITY	2,395	3,656	12,580	19,225	27,302
NON-CURRENT LIABILITIES	92	117	63	88	302
BORROWINGS	15	81	54	32	43
CURRENT LIABILITIES	2,428	2,383	2,460	2,741	5,227
BORROWINGS	1,188	663	27	22	1,030
TRADE PAYABLES	328	463	607	446	950
TOTAL EQUITY & LIABILITIES	4,915	6,155	15,103	22,053	32,831
NON-CURRENT ASSETS	2,306	3,951	7,355	7,619	17,615
PROPERTY, PLANT AND EQUIPMENT	2,250	2,822	5,969	6,683	9,234
CAPITAL WORK-IN-PROGRESS	0	504	113	350	1,123
CURRENT ASSETS	2,609	2,204	7,748	14,434	15,216
INVENTORIES	928	576	410	350	295
TRADE RECEIVABLES	324	897	2,207	4,119	9,763
CASH AND CASH EQUIVALENTS	896	257	3,239	6,201	2,596
TOTAL ASSETS	4,915	6,155	15,103	22,053	32,831

5Y *Cash Flow Statement*




PARTICULARS	FY21	FY22	FY23	FY24	FY25
CASH FROM OPERATING ACTIVITIES	1,752.76	1,747.95	1,716.94	3,668.93	6,862.68
CASH FROM INVESTING ACTIVITIES	(858.90)	(1,963.76)	(5,723.16)	(1,804.61)	(7,036.81)
CASH FROM FINANCING ACTIVITIES	(153.22)	(451.08)	4,800.34	(344.39)	(69.14)
NET CASH FLOW	740.64	(666.89)	794.12	1,519.93	(243.27)
CASH AT BEGINNING OF YEAR	143.66	884.30	217.42	1,011.54	2,531.47
CASH AT END OF YEAR	884.30	217.41	1,011.54	2,531.47	2,288.20

Market *Statistics*

NSE Symbol	<u>JSLL</u>
BSE Scrip Code	<u>544476</u>
Listing Date	
- NSE	April 19, 2022
- BSE	August 11, 2025
Current Market Price	₹712.50
52 Week High/Low	₹849.50/₹280.00
Shares Outstanding	12.43 Cr
Market Capitalization	₹8,856.43 Cr
Industry Classification	Healthcare

Note: Market Price Data as on 6th February 2026



Note: Shareholding Data as on 31st December 2025

Contact Us

Contact Details

Nanak Chand
Chief Financial Officer
Email Address: investors@jeenasikho.com

ADDRESS:

Jeena Sikho Lifecare Limited
SCO 11, First Floor, Kalgidhar enclave, Kalka
Shimla Highway, Near K-Area Road, Baltana
Light Point, Zirakpur, **CHANDIGARH**
District Mohali, Punjab - 140604

Investor Presentation

Q3 FY26 | February 2026

This document which have been prepared by Jeena Sikho Lifecare Limited (the "Company" or "JSLL"), have been prepared solely for information purposes. This document has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Document. This Document may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Document is expressly excluded.

Certain matters discussed in this Document may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Document. The Company assumes no obligation to update any forward-looking information contained in this Document. Any forward-looking statements and projections made by third parties included in this Document are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

